In breast cancer, it upregulates the expression of dihydrofolate reductase (DHFR), a target of the chemotherapeutic drug methotrexate, enhancing the proliferation and chemoresistance of breast cancer cells (Nakano et al., 2017). The gene discussed is DHFR; the disease is breast carcinoma.